IT

Dexcom
see what’s new with the #1 CGM brand in patient satisfaction*,†

We look forward to meeting you at ATTD!

Attend our symposia or in-booth sessions to learn about our latest breakthroughs. Visit our booth to learn about our latest product innovations. Experience Dexcom rt-CGM in a new way through a mix of digital and physical displays.

Discover Dexcom at booth #82

Meet the new Dexcom ONE+
Product availability varies by country
Demo upcoming features on the
Dexcom G7
Take on your peers in our 
Type 2 challenge
Discover our new connections
in our partner corner

Join our clinical sessions

Hear exciting updates on CGM guidance and research and learn the latest on all the ways Dexcom products can support all types of diabetes patients. We have an action-packed agenda ahead! See our schedule below for a preview of presentation topics.
Educational Resources
Wednesday, 6 March | 14:40 - 16:10 | Hall C

Dexcom Innovation:
AID, Smart Devices and EHR Integration for Enhanced Care

We are excited to kick off ATTD 2024 with the latest Dexcom innovations for connectivity and exclusive data on improved outcomes for people living with Type 1 Diabetes.

Moderator​: Professor Partha Kar, FRCP​

AID: Advancing Practice & Access

Professor Partha Kar, FRCP | England, United Kingdom

  • Consultant Endocrinologist, Portsmouth Hospitals
  • National Specialty Advisor, Diabetes NHS England

AID Powered by Dexcom CGM

Gregory P. Forlenza, MD | Colorado, United States​

  • Associate Professor, Barbara Davis Center

CGM & AID use in Pregnancy

Professor Helen R. Murphy MBBChBAO, FRACP, MD | Norwich, United Kingdom​

  • Professor of Medicine, University of East Anglia (UEA)

Dexcom CGM is Made for Connections

Anita Swamy, MD | Illinois, United States​

  • Assistant Professor, Northwestern University Feinberg School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology
  • Associate Clinician, Ann and Robert H. Lurie Children’s Hospital of Chicago​

Dexcom EHR Integration

Grazia Aleppo, MD, FACE, FACP | Illinois, United States​

  • Professor of Medicine, Feinberg School of Medicine, Northwestern University, Chicago ​

Thursday, 7 March | 14:40 - 16:10 | Hall A

Dexcom Breakthroughs:
Leveraging CGM Early and Across the Spectrum of
Type 2 Diabetes Care

Be the first to learn about Dexcom’s newest system, Dexcom ONE+ and access the latest research across the Type 2 spectrum.

Moderator: Sufyan Hussain, MA, MB BChir, MRCP, PhD​​

Introducing Dexcom ONE+

Sufyan Hussain, MA, MB BChir, MRCP, PhD | London, England​

  • Consultant Physician in Diabetes & Endocrinology, Guy’s & St Thomas NHS Foundation Trust ​
  • Honorary Senior Clinical Lecturer, Department of Diabetes, School of Cardiovascular, Metabolic Medicine and Sciences, Kings College London ​
  • Member, Board of Directors, International Diabetes Federation, Europe​

Dexcom CGM Improves Outcomes in Insulin-treated Type 2 Diabetes

Associate Professor Martin de Bock, FRACP, PhD | Christchurch, New Zealand ​

  • Paediatric Endocrinologist, Department of Paediatrics, University of Otago

The Evolution of Glycemic Targets: Time in Tight Range

Viral N. Shah, MD | Indiana, United States​

  • Professor of Medicine, Division of Endocrinology & Metabolism, Director of Diabetes Clinical Research, IU Center for Diabetes and Metabolic Diseases

Dexcom CGM Improves Outcomes in Non-insulin Treated Type 2 Diabetes

Richard M. Bergenstal, MD | Minnesota, United States​

  • Executive Director, International Diabetes Center, HealthPartners Institute ​
  • Clinical Professor, Department of Medicine, University of Minnesota​

The Synergistic Impact of Dexcom CGM & GLP-1 Agonists

Davida F. Kruger, MSN, APN-BC, BC-ADM | Michigan, United States​

  • Certified Nurse Practitioner, Henry Ford Health System, Division of Endocrinology, Diabetes, Bone and Mineral Disease ​

Friday, 8 March | 8:30 - 9:20 | Hall C

Dexcom Transformation:
Improving Lives of People with Type 2 Diabetes​

In this panel moderated by William Polonsky, we will uncover new data around the behavioral impact of CGMs on Type 2 patients.

Moderator: William H. Polonsky, PhD, CDCES 

Dexcom CGM Making the Invisible Visible in Type 2 Diabetes

William H. Polonsky, PhD, CDCES | California, United States​

  • President, Behavioral Diabetes Institute ​
  • Associate Clinical Professor, University of California, San Diego​

Dexcom ONE+ in Clinical Practice

Dr Sarah Davies, MBBCh (hons), FRCP, MRCGP, PGDip Diabetes | Wales, United Kingdom​

  • GP Woodlands Medical Centre, Cardiff​
  • Clinical Director for Diabetes in Primary Care, Cardiff and Vale UHB
  • National Lead for Diabetes in Primary Care for Wales

Dexcom CGM for Population Health

Thomas Grace, MD, CDCES, Board-Certified Family Medicine, ABOM | Ohio, United States​

  • Director, Blanchard Valley Diabetes Center
  • Head, Clinical Advocacy and Outcomes, Dexcom

All symposia presentations will be available on-demand after the conference on our free SIGMA platform and on the ATTD website.

Industry Symposia are not included in the main Conference CME/CPD credit.
SIGMA Platform

Dexcom in‑booth presentations

Hear in-depth discussions from our Clinical Education team on the many advancements Dexcom is making in the rt-CGM space.

Wednesday, 6 March

19:15 - 19:30
Meet the New Dexcom ONE+: a Smarter1, Easier1-3, and More Effective1,4-7 Way to Manage Diabetes



Thursday, 7 March

10:15 - 10:30
Dexcom G7: Advanced Monitoring Made Simple
12:15 - 12:45
Dexcom Connections Series
16:20 - 16:35
Making it Easier1 to Achieve Lasting Results 4,7,8,‡ with Dexcom ONE+



Friday, 8 March

10:45 - 11:00
Achieve Superior Outcomes Using Dexcom Clarity
12:45 - 13:15
Dexcom Connection Series
17:00 - 17:15
Meet the New Dexcom ONE+: a Smarter1, Easier1-3, and More Effective1,4-7 Way to Manage Diabetes

Discover which Dexcom rt‑CGM systems are available in your region.

Discover Dexcom
Side image
Product availability varies by country.
*Comparison of NPS scores of Dexcom, Abbott and Medtronic, Seagrove Survey 2023 Patients Perspectives.
†Based on a survey of patients with Type 1 and Type 2 Diabetes conducted in the United States n=310.
‡ Study included non-Dexcom CGM system.
1 Compared to Blood Glucose Meter.
2 Results obtained with Dexcom G7 study, which shares similar features and usability.
3 Dexcom Data on File, 2022.
4 Results obtained with a previous generation of Dexcom CGM system and are applicable to Dexcom ONE+ given similar feature sets and better performance and usability.
5 Beck RW et al. Ann Intern Med. 2017;167(6):365-374.
6 Lind M, et al. Diabetes Care. 2021;44(1):141-149.
7 Welsh JB, et al. J Diabetes Sci Technol. 2024; 18(1):143-147.
8 Soupal J, et al. Diabetes Care. 2020; 43: 37-43.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries.

MAT-1655 V1.0